The Cardiovascular Research Unit aims to better understand the role of RNAs in heart and brain diseases. Our goal is to develop RNA-based biomarkers and therapeutic approaches to personalise health care. Our current focus is on heart failure, cardiac arrest and Parkinson’s disease.
MICRA is a very promising biomarker candidate due to its stability in the blood allowing a quantification in blood samples.Yvan Devaux, PhD, Head of the Cardiovascular Research Unit (CVRU)
Our ongoing Research Projects address two major areas.
Using high-throughput transcriptomics tools, the team seeks to develop RNA-based diagnostic and prognostic biomarkers for cardiovascular and brain diseases. Research projects focus on non-coding RNAs: microRNAs, long non-coding RNAs, and circular RNAs.
By focusing on the mechanisms by which RNAs regulate the development of diseases, the group aims to facilitate drug discovery.
CardioRNA COST Action CA17129 is a pan-European collaborative network of multidisciplinary researchers, clinicians and industrial partners which aims to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and to further translate experimental data into applications that can be used to improve personalised medicine in this field.
CardioRNA aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, enabling the functions of different RNAs and their interactions in the cardiovascular context to be deciphered more quickly and translated into clinical applications. This Action will result in grant proposals aimed at better understanding the role of the transcriptome in cardiovascular disease and translating the results into clinical applications, thereby promoting personalised medicine and addressing a current public health challenge.
The group also coordinates the H2020 COVIRNA project which aims to develop RNA-based prognostic tools for COVID-19 patients (www.covirna.eu).
The group is partner of IMI2 CARDIATEAM project (www.cardiateam.eu) and EU-Cardioprotection COST Action CA16225 (www.cardioprotection.eu).